These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25271612)

  • 21. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
    Burstein HJ; Griggs JJ
    J Clin Oncol; 2012 Mar; 30(7):684-6. PubMed ID: 22271478
    [No Abstract]   [Full Text] [Related]  

  • 22. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?
    Partridge AH
    J Clin Oncol; 2012 Feb; 30(5):479-81. PubMed ID: 22231046
    [No Abstract]   [Full Text] [Related]  

  • 23. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of ovarian suppression in the combined treatment of breast cancer patients in premenopause].
    Shchepotin IB; Zotov AS; Liubota RV; Anikus'ko NF; Liubota II
    Vopr Onkol; 2013; 59(3):397-404. PubMed ID: 23909046
    [No Abstract]   [Full Text] [Related]  

  • 25. Are SOFT and TEXT results practice changing and how?
    Pagani O; Regan MM; Francis PA
    Breast; 2016 Jun; 27():122-5. PubMed ID: 27107153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
    Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
    Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
    [No Abstract]   [Full Text] [Related]  

  • 27. Longer time to tumor progression with exemestane vs tamoxifen in advanced breast cancer.
    Oncology (Williston Park); 2000 Sep; 14(9):1291, 1294. PubMed ID: 11033826
    [No Abstract]   [Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Blumenfeld Z
    J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant treatment of breast cancer with exemestane.
    Vakaet LA; De Neve W
    N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237462
    [No Abstract]   [Full Text] [Related]  

  • 30. Exemestane or tamoxifen?
    Atkins CD
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
    [No Abstract]   [Full Text] [Related]  

  • 31. Ovarian cyst formation in two pre-menopausal patients treated with tamoxifen for breast cancer.
    Shulman A; Cohen I; Altaras MM; Maymon R; Ben-Nun I; Tepper R; Beyth Y
    Hum Reprod; 1994 Aug; 9(8):1427-9. PubMed ID: 7989499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.
    Tomao F; Benedetti Panici P; Tomao S
    J Clin Oncol; 2012 Sep; 30(26):3310-1; author reply 3312-3. PubMed ID: 22649128
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant treatment of breast cancer with exemestane.
    Kunkler IH
    N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15229316
    [No Abstract]   [Full Text] [Related]  

  • 34. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
    Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
    JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin.
    Meattini I; Saieva C; Meacci F; Scotti V; De Luca Cardillo C; Desideri I; Baldazzi V; Mangoni M; Scoccianti S; Detti B; Simontacchi G; Nori J; Orzalesi L; Sanchez L; Casella D; Bernini M; Fambrini M; Bianchi S; Livi L
    Future Oncol; 2016 Mar; 12(5):625-35. PubMed ID: 26837239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into endocrine therapy for young women with breast cancer.
    Di Lascio S; Pagani O
    Womens Health (Lond); 2015 Jun; 11(3):343-54. PubMed ID: 26102472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.